Unity Biotechnology Inc (NASDAQ:UBX) stock has reached a 52-week high, trading at $2.02, signaling a period of robust ...

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...

Sam Altman-backed Retro Biosciences is raising $1 billion to develop drugs that extend human lifespan by 10 years, the FT ...

Unity Biotechnology Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of 76.03%. The profit margin, also known as the revenue ratio or gross profit ratio ...

Fintel reports that on January 10, 2025, Chardan Capital initiated coverage of Unity Biotechnology (NasdaqGS:UBX) with a Buy ...

OpenAI CEO Sam Altman backs Retro Biosciences, a San Francisco-based biotech start-up that wants to extend human lifespan by ...

UNITY Biotechnology has appointed Federico Grossi, M.D., Ph.D., as its new chief medical officer to enhance its leadership team. Dr. Grossi, who has over 20 years of experience in biotech ...

Stock analysts at Chardan Capital started coverage on shares of Unity Biotechnology (NASDAQ:UBX – Get Free Report) in a research note issued to investors on Friday, Marketbeat.com reports. The firm ...

SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging ...

Unity Biotechnology, Inc. SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to ...